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Cardiovascular disease is the leading cause of morbidity and mortality in the U.S. Metabolic 
syndrome with its associated comorbidities is a major contributor to cardiovascular disease. 
There is a significant prevalence of schizophrenia in the U.S. and a high prevalence of 
cardiovascular disease in this patient population. Metabolic syndrome has significant prevalence 
in patients with schizophrenia who take atypical antipsychotics ((Riordan et al, 2011). In order to 
further analyze the relationship between the various atypical antipsychotics and metabolic 
syndrome in patients with schizophrenia a literature review was conducted. This review also 
aimed to find literature offering treatment modalities effective against combating this problem. 
Cochrane, PubMed and PsycInfo were used to identify the relevant literature from the past ten 
years. Among the commonly used atypical antipsychotics, clozapine was found to have the most 
association with metabolic syndrome while ziprasidone had the least. Metformin in conjunction 
with lifestyle modifications was shown to be the most effective in inducing weight loss, reduce 
BMI and effectively treat metabolic syndrome. This literature review also highlights the 
important role played by APRNs and nurses in the context of the Health Promotions Model in 













Atypical Antipsychotics and Metabolic Syndrome 
Schizophrenia is a serious, long-term and debilitating mental health disorder that can 
affect any demographic group. It is characterized by impairments and deficits in cognition, 
sensory perception and emotion (NIH, 2016). It affects roughly 1.1% of the U.S. adult 
population with only 60% of the affected seeking healthcare (Regier et al, 1993). Worldwide, the 
prevalence of schizophrenia is between 0.5-1.0% with men manifesting the disease early 
compared to women. Suicidality is a major feature of schizophrenia with roughly one-third 
attempting suicide and 10% of the attempts resulting in completion. In addition, schizophrenia 
carries with it substantial financial costs for a nation’s economy. Health care costs and costs 
associated with loss of productivity added up to approximately $6.85 billion in 2004 (CDC, 
2013).  
The mainstay of medical treatment for schizophrenia is the use of typical and atypical 
antipsychotics directed at the neurotransmitter dopamine. The goal of treatment is to control 
symptoms and patients are treated for the rest of their lives even during symptom free periods. 
Due to the higher risk of side effects such as movement disorders (ex. Tardive dyskinesia) with 
the first generation (typical) antipsychotics, second generation antipsychotics – also called 
atypicals – are preferred (Mayo, 2016). In an effort to avoid the side effects of typical 
antipsychotics, atypical antipsychotics have increasingly been used. However, a major 
unintended side effect of the atypical antipsychotics has been the increased incidence of 
cardiovascular disease which is the leading cause of mortality in patients with schizophrenia.  
Studies have already established a significant relationship between atypical 
antipsychotics and metabolic syndrome possibly leading to cardiovascular morbidity and 
mortality (Riordan et al, 2011). Metabolic syndrome is characterized by high fasting 





hyperglycemia, hypertension, central obesity, and dyslipidemia. It is anticipated to become the 
number one risk factor for ischemic heart disease independent of a schizophrenia diagnosis 
(NIH, 2016). With ischemic heart disease as a leading cause of death in the U.S (1 in 4 deaths) 
(CDC, 2015) and contributed to by metabolic syndrome, this serves as an opportunity to further 
analyze the side effect profiles of the various atypical antipsychotics available on the market. 
This literature review aims to inform our choice of atypical antipsychotics and provide 
guidelines for monitoring the various aspects of metabolic syndrome in this particular 
demographic. 
Purpose 
 Given the above-mentioned scope of problem with usage of atypical antipsychotics and 
their association with metabolic syndrome and its outcome, the usage of these medications needs 
to be further characterized. This project will focus on examining the various atypical 
antipsychotics used in the care of patients with schizophrenia. It will also attempt to stratify each 
commonly used medication – as the literature review allows – based on their side-effect profile 
relating to metabolic syndrome. This will examine any potential or documented cause-effect 
relationships between atypical antipsychotics and the various components of the metabolic 
syndrome. 
 The first step in the review process will be to identify atypical antipsychotics commonly 
used in treatment. This will be implemented by reviewing the latest guidelines from major 
reputable sources in the treatment of schizophrenia. This search will further identify the types of 
atypical antipsychotics that are used in the treatment of this disease. Next, the nature of 
metabolic syndrome with its extent of disease burden, morbidity and mortality will be detailed to 
set the stage for the analysis of the medications and their degree of involvement with metabolic 





syndrome. The main aim of this literature review is to inform the psychiatric mental health 
practitioner of the varying degrees of association between certain atypicals with metabolic 
syndrome in order to shape his/her choices when treating patients with schizophrenia with the 
ultimate benefit of preventing morbidity and mortality in this patient group. 
Significance 
 Schizophrenia exists in 1.1% of the US population with more than half of these patients 
seeking healthcare (Regier et al, 1993). Since the use of atypical antipsychotics is very prevalent 
in this demographic, this implies that a large number of people are at risk or are already affected 
by metabolic syndrome and its consequences such as ischemic heart disease. With 1 in 4 deaths 
in the US attributed to ischemic heart disease (CDC, 2015), it is safe to imply that atypical 
antipsychotics ultimately contribute to this statistic through their relationship with metabolic 
syndrome.  
 This relationship between atypical antipsychotic use and mortality from ischemic heart 
disease has multiple points of intervention which mainly revolve around understanding and 
choosing the right antipsychotic medications, individualizing therapy based on patients’ unique 
co-morbidities, and implementing appropriate follow-up plans to monitor patients for metabolic 
syndrome. These areas of intervention can be capitalized on by health care practitioners 
including psychiatric mental health nurse practitioners to minimize this very undesirable side 
effect of pharmacotherapy in schizophrenic patients.  
Potential areas of intervention include but are not limited to developing health screening 
methods to stratify each patient based on risk factors for metabolic syndrome; developing a work 
flow for electronic medical records to identify patients with the risk factors, abnormal vital signs 
and lab results (ex. high BMI, High blood pressure, Low HDL, high triglyceride, high fasting 





blood sugar (NIH, 2016)); providing point of care resources that inform and remind staff of the 
different efficacies and side-effect profiles of atypical antipsychotics; reserving a special list for 
a panel of patients on atypical antipsychotics and designating a clinic staff (ex. RN) to follow up 
and recall patients on atypical antipsychotics for follow up labs; and holding information 
sessions at local healthcare centers, providing lectures, and presenting at major conferences to 
promote awareness and provide recommendations. This study seeks to integrate the findings 
from pre-existing literature regarding the association between atypical antipsychotics and 
metabolic syndrome and provide recommendations to minimize or prevent this association and 
ultimately avoid morbidity and mortality in our schizophrenia patient population. 
Theoretical Framework 
 A major social theory that will provide the appropriate conceptual basis of this study is 
the Health Promotions Model (HPM) by Nola Pender developed in 1982 and later refined. It 
integrated the expectancy-value theory and social cognitive theory which formed the basis of 
HPM from a nursing perspective. This model approached health promotion from the perspective 
that, behaviors that lead to increased health result from certain biopsychosocial factors that 
influence individuals’ motives. The major components of the HPM are behavior-specific 
cognitions/affect, personal characteristics/experiences, and behavioral outcomes. Psychosocial 
factors and behaviors form a major barrier to the care of patients with schizophrenia. The 
theoretical framework suggested by the HPM takes this into account by focusing on these 
barriers and shifting the focus to the health promotion of populations through understanding our 
patients, their circumstances and implementing change (McEwen et al, 2011). Therefore, in 
addition to medication adjustments in schizophrenic patients with metabolic syndrome who take 





atypical antipsychotics, biopsychosocial processes that play a major role in the patients’ care can 
also be explored and changed to promote a more favorable outcome for this patient population.  
 This theoretical framework is therefore very useful in identifying areas of intervention in 
the prevention, screening, treatment and regular follow up of patients with schizophrenia who are 
at risk of developing or who have developed metabolic syndrome. As it will be explored in the 
literature review, a major threat to the validity of these studies is anticipated to arise from the 
loss to follow-up of patients with schizophrenia. The diagnosis of schizophrenia independently 
affects lifestyle choices leading to metabolic syndrome as well as interfere with the regular 
screening schedules for and the treatment of metabolic syndrome in schizophrenic patients being 
treated with atypical antipsychotics. 
Definitions 
 The patient population in the literature review is any patient with the diagnosis of 
schizophrenia who is currently receiving treatment with atypical antipsychotics. Atypical 
antipsychotics are any of the second generation antipsychotics that are currently widely used to 
treat schizophrenia in all age groups. Metabolic syndrome constitutes a group of endocrine and 
metabolism derangements contributing to cardiovascular mortality. Hypertriglyceridemia is 
elevation of triglycerides in the blood. Hyperglycemia is elevation of glucose in the blood and is 
the hallmark of diabetes mellitus.  
Literature Review 
Overview 
 This literature review aims to present publications pertaining to metabolic syndrome and 
its associated symptoms in schizophrenic patients treated with atypical antipsychotic 
medications. Literature describing the nature of metabolic syndrome in the setting of atypical 





antipsychotic use, its presentation, its risk factors (genetic and environmental), associated co-
morbid conditions and overall implications will be discussed. The bulk of this review section 
will also be dedicated to presenting the various atypical antipsychotics in use and compare their 
side-effect profile as it pertains to metabolic syndrome. Comparative efficacy of these 
medications will also be discussed where appropriate. A portion of this review section will also 
address the efficacy of certain modalities used in treatment and monitoring of metabolic 
syndrome in patients with schizophrenia who take atypical antipsychotics. 
 
Metabolic Syndrome and Cardiovascular Mortality 
 In line with the statistics of the general population without the diagnosis of schizophrenia, 
cardiovascular disease is also the number one cause of mortality in patients with schizophrenia. 
30% of all deaths in the US are attributed to a cardiovascular cause. It has been established that 
metabolic syndrome as a side-effect of atypical antipsychotic use largely contributes to the 
cardiovascular mortality of patients with schizophrenia with roughly 1/3rd of deaths attributed to 
a cardiovascular cause. With 2.2 million American adults affected by schizophrenia and with the 
ubiquitous use of atypical antipsychotics potentially contributing to 20-60% prevalence of 
metabolic syndrome in these patients, the disease and financial burden on our patients and the 
healthcare system is significant (Riordan et al, 2011). This patient demographic has also been 
noted to have a 1.5 to 2 times more likelihood of developing obesity, hypertension, 
hyperlipidemia, and type 2 diabetes mellitus, diseases that constitute metabolic syndrome. This 
risk is in addition to their risk of developing this syndrome independent of atypical antipsychotic 
use. Metabolic syndrome is defined by five parameters which include large waist circumference 
(35 inches or above for women; 40 inches or above for men); high triglyceride level (150 mg/dL 





or above); low HDL (less than 40 mg/dL in men and 50 mg/dL in women; blood pressures 
130/85 or higher; and high fasting glucose (100 mg/dL or higher) (Mayo, 2016). Per the 
International Diabetes Federation, patients with central obesity and two of the other factors meet 
the criteria for metabolic syndrome (Riordan et al, 2011). The components of the syndrome are 
otherwise commonly diagnosed in the general population raising the likelihood of a shared 
metabolic/endocrine pathway that underlies these disease processes and is affected by atypical 
antipsychotics. Various mechanisms have been proposed that link these medications to metabolic 
syndrome including regulation of gene expression, dopamine, histamine, anabolic neuropeptides, 
neuronal receptors, and failure of glucose regulation (Coccurello et al, 2010, Mulder et al, 2007, 
Liou et al, 2013). Poor life-style choices such as physical inactivity, smoking, and poor diet 
associated with the diagnosis of schizophrenia are also major contributors to the development 
this syndrome (Riordan et al, 2011).  
 
Genetic Predisposition to Metabolic Syndrome in Atypical Antipsychotic Use 
Certain genetic variants have also been identified that may play a role in the pathway that 
links atypical antipsychotic treatment and metabolic syndrome. Certain variations or 
polymorphisms in the serotonin receptor gene identified as 5-hydroxytryptamine receptor 2C 
(HTR2C) were previously implicated in diabetes and obesity in the general population. This was 
a cross-sectional study drawing 112 patients from a pool of 200,000 patients with 
schizophrenia/schizoaffective disorders. The study patients were treated with clozapine, 
olanzapine and risperidone and were followed using strict parameters (blood pressure, 
triglycerides, HDL, and waist circumference) with the primary endpoint being metabolic 
syndrome. One variation of this gene termed HTR2C rs3813929 was linked to atypical 





antipsychotic use and metabolic syndrome (Mulder et al, 2007). Another study added that 
another HTR2C polymorphism typed rs 1414334 was strongly associated with clozapine and 
risperidone use leading to metabolic syndrome. Furthermore, a polymorphism in the MTTP gene 
typed MTTP rs 1800591 conferred increased risk of metabolic syndrome. This was a gene 
involved in triglyceride metabolism (Liou et al, 2013). This was also a cross-sectional study but 
with a larger sample size (n=456) and with a more stringent inclusion and exclusion criteria. It 
used the same 3-month follow-up time after initiation of the same antipsychotics (clozapine, 
olanzapine, risperidone) as the previous study but defined metabolic syndrome in terms of the 
International Diabetes Federation criteria as described earlier by Mayo Clinic. These studies both 
used accepted criteria to define metabolic syndrome and raised congruent points that highlight 
the contribution genetic variations can make in predisposing schizophrenic patients with atypical 
antipsychotics to metabolic syndrome.  
 
Cost of Care 
With regards to the total cost of care for patients with schizophrenia on atypical 
antipsychotics, there was no short-term difference in cost. Despite the higher risk of diabetes and 
weight gain with olanzapine compared with risperidone, a head-to-head comparison of the total 
monthly cost of care did not reveal a significant difference (Riordan et al, 2011). Whether there 
is a long-term difference in healthcare cost between the other atypical antipsychotics is unclear 









Direct Comparison Between the Atypicals 
 Seven systematic reviews of randomized controlled trials performed a head-to-head 
comparison of the efficacy and side effect profiles of the various atypical antipsychotics on the 
market including clozapine, olanzapine, aripiprazole, amisulpride, risperidone, ziprasidone, 
quetiapine, sertindole, and zotepine Among the side effects compared were risk of metabolic 
syndrome and its constituents, weight gain and diabetes. The purpose of these systematic reviews 
was to select one atypical antipsychotic and compare its efficacy and side effect profile with the 
rest of the medications in its class. Regardless of the increased efficacy, clozapine was associated 
with the highest risk of inducing metabolic syndrome, with olanzapine as the second highest 
cause. Both medications also carried the most risk of inducing type II diabetes mellitus compared 
to the others in their class (Komossa et al, 2010). On further exploration, the seven systematic 
reviews had various points of agreement as well as discrepancy when stratifying the metabolic 
risk profile for each atypical antipsychotic. After first taking into account the systematic reviews’ 
common findings regarding the risk of developing metabolic syndrome, the atypical 
antipsychotics can be stratified as such based on their metabolic risk profile from the highest to 
the lowest: clozapine > olanzapine > quetiapine/sertindole > risperidone > 
amisulpride/aripiprazole > ziprasidone. Medications grouped together and not stratified further 
within the spectrum indicates lack of adequate comparative data to draw firm conclusions. Along 
the same line, direct comparisons of quetiapine with amisulpride, sertindole and zotepine were 
not performed (Asmal et al, 2013). In addition, amisulpride was only compared head-to-head 
with olanzapine and risperidone in which it showed less risk of weight gain. But, comparison 
with ziprasidone was inconclusive (Komossa et al, 2010). However, in a direct comparison 
Ziprasidone had a lower metabolic risk profile compared to amisulpiride, olanzapine and 





risperidone (Komossa et al, 2009). With regards to comparison of risperidone’s metabolic risk 
profile with the other medications on the spectrum, definitive conclusions could not be drawn but 
worse metabolic risk profile was suggested when compared with amisulpride, aripiprazole and 
ziprasidone (Komossa et al, 2011). In a similar fashion, sertindole was only compared with 
risperidone and it showed increased metabolic risk profile (Komossa et al, 2009). Clozapine also 
showed more risk of weight gain compared to risperidone (Asenjo et al, 2010). 
 The discrepancies between some of the systematic reviews with regards to risk of 
metabolic syndrome and associated conditions mainly occurred in the study that compared 
quetiapine with the other medications. Due to discontinuation of therapy by a significant number 
of patients (60%) within a few weeks, this systematic review could not establish a meaningful 
comparison of quetiapine with risperidone, clozapine and aripiprazole with which it was 
purported to have similar metabolic risk profile (Asmal et al, 2013). However insignificant, 
quetiapine’s standing in comparison to the other medications on the metabolic risk spectrum 
happens to be supported by the other studies. Despite the systematic reviews analyzing as many 
as 50 randomized-controlled trials in the olanzapine study (Komossa et al, 2010), and 45 
randomized-controlled trials in the risperidone study (Komossa et al, 2011), no firm conclusions 
could be drawn from them due to the overall high attrition rate in these studies approaching 60% 
which threatens their internal validity. In addition, the review that analyzed Sertindole only 
included 2 studies (Komossa et al, 2009) and the review that looked at Amisulpride was only a 
short to medium term study (Komossa et al, 2010). Despite the above-mentioned obstacles to 
drawing solid conclusions, some suggestions can be made – as laid out in the metabolic risk 
profile spectrum in the previous paragraph – with regards to the various atypical antipsychotics 
and their associated risk of metabolic syndrome. Another study was conducted that also 





highlighted the increased risk of metabolic side effects with four atypical antipsychotics 
(aripiprazole, olanzapine, quetiapine, and risperidone). This was a randomized study with a 
design that consisted of complete randomization and clinician’s choice methods where 1 or 2 
medications can be excluded per psychiatrist or patient wishes. Despite the high therapy 
discontinuation rate and shorter duration of treatment (median 26 weeks), a high cumulative 
incidence of metabolic syndrome was still noted (36.5% in 1 year) for all of the atypical 
antipsychotics in the study. The randomization method in this study appears suitable for this 
patient population since it accounts for the “real world” adjustments that take place in response 
to the medications’ side effects. If the study was done with true double-blinded fashion, 
significantly less number of patients would stay within the group since they most likely would 
not tolerate the side-effect. This study’s design gave patients the option to leave out 1-2 of the 
medications and stay longer within the study. The high attrition rate, shorter duration of 
treatment, prior exposure to atypical antipsychotics, inclusion of various psychiatric diagnoses 
and age group of subjects > 40 years all negatively affect the internal and external validity of the 
study. Despite the limitations, these four commonly used atypical antipsychotics were associated 
with higher incidence of metabolic syndrome (Jin et al, 2013). 
 
Periodic Monitoring of Metabolic Syndrome in Atypical Antipsychotic Use 
 Patients who are on atypical antipsychotics require frequent monitoring for and potential 
treatment of metabolic syndrome and the different derangements/diagnoses it carries (i.e. 
hypertension, obesity, hyperlipidemia, impaired fasting glucose). Risk factor modification is the 
focus of managing metabolic syndrome in an effort to prevent cardiovascular mortality and 
includes adjusting diet, exercising, achieving adequate blood pressure control, and treating 





hyperlipidemia/hyperglycemia (Riordan et al, 2011). Furthermore, multiple atypical 
antipsychotic use was not associated with increased risk of metabolic syndrome compared with 
single medication use. Nonetheless, initiation of periodic monitoring of blood pressure, fasting 
lipid panel and glucose is recommended in patients who start taking atypical antipsychotics. 
Riordan et al point out that only a minority of the patients do actually get monitored for these 
parameters of the metabolic syndrome. The proposed recommendations for monitoring include 
measurements at baseline, at 4 weeks, at 8 weeks, at 12 weeks, every 3 months, every year and 
every 5 years. Periodic metabolic monitoring in these patients is essential given their 
vulnerability (Riordan et al, 2011). 
 
Treatment of Metabolic Syndrome in Schizophrenic Patients on Atypical Antipsychotics 
 Treatment of metabolic syndrome in these patients includes risk factor modification 
through lifestyle changes and pharmacotherapy. Lifestyle modifications include behavioral 
therapy, dietary guidance and enrollment in an exercise program (Wu et al, 2008). 
Pharmacotherapy includes off-label use of metformin for better glycemic control (Wu et al, 
2008, Jesus et al, 2015). The study that examined the role of lifestyle modifications and 
metformin use was a randomized controlled trial that assigned 128 patients with schizophrenia to 
4 groups: placebo, lifestyle modification only, metformin only, and lifestyle modification with 
metformin. The patient population was selected carefully and the subjects were 18-45 years with 
their first psychotic episode of schizophrenia diagnosed using the DSM-IV. Weight gain of more 
than 10% of their weight prior to initiating the atypical antipsychotics (clozapine, olanzapine, 
risperidone, and sulpiride) was used as inclusion criteria. Strict monitoring of the patients’ 
lifestyle, including diet intake was instituted. Lifestyle modification plus metformin use at 750 





mg per day showed the most effect on weight loss, decrease in BMI, and reduction in waist 
circumference. This group had a mean BMI decrease of 1.8, insulin resistance index decrease of 
3.6 and decrease in waist circumference of 2.0. Metformin alone was also found to be better than 
lifestyle modification alone (Wu et al, 2008). This was a very well designed and very well 
implemented study with stringent inclusion and exclusion criteria as well as close follow up. It 
has very good internal validity but can only be generalized to the age group between 18-45 years. 
The benefit of metformin in atypical antipsychotic-induced metabolic syndrome was supported 
by a review article which showed that metformin use in this patient population resulted in better 
glycemic control, improved weight loss and these effects were evident in patients with and 
without diabetes. In contrast to the trial by Wu et al, metformin in this review of 12 articles was 
especially beneficial when started in young adults who are initiated on these medications (Jesus 
et al, 2015). Additionally, a meta-analysis of four randomized trials and 105 patients concluded 
that metformin use resulted in approximately 5% weight reduction in patients on olanzapine who 
had developed metabolic syndrome. This weight reduction was more than the weight loss 
achieved by other approved medications such as orlistat and sibutramine. Furthermore, the 
adverse effects of metformin were similar to placebo (Praharaj et al, 2010). This meta-analysis 
had no significant heterogeneity but only consisted of 4 randomized trials with a small pooled 
sample size. 
 This extensive Literature review shows that atypical antipsychotics are associated with a 
greater risk of developing metabolic syndrome especially in patients with schizophrenia. 
Furthermore, despite the lack of strong conclusions from the reviewed studies, there exists a 
spectrum of metabolic risk profile for these medications with each atypical antipsychotic falling 
somewhere on the spectrum from highest to the lowest risk. Among the medications reviewed, 





the consensus is that clozapine is deemed to have the highest risk while ziprasidone has the 
lowest risk of leading to metabolic syndrome. However, the high attrition rate in most of the 
systematic reviews comparing the medications has resulted in the lack of a strong comparison 
between the different medications in this class. There is strong evidence that Metformin in 
conjunction with a healthy diet and exercise has shown the maximum benefit in reducing weight, 
BMI, and waist circumference in patients with atypical antipsychotic-induced weight gain even 
when compared to standard weight-reduction pharmacotherapy. 
Methods 
 An online search was conducted through the Harley E. French Biomedical Library at the 
University of North Dakota. In an effort to identify the highest level of evidence the literature 
search was initiated with the Cochrane database of systematic reviews. The search terms 
“atypical”, “antipsychotics”, “metabolic” were used yielding 604 results. A filter was applied to 
identify those grouped under mental health which narrowed the results to 179. The subgroup 
filter was applied isolating those dealing with Schizophrenia and Psychosis which narrowed the 
results to 142. The list was further narrowed to 43 by further specifying atypical antipsychotics. 
Seven systematic reviews comparing the various atypical antipsychotics including their risk 
profile for developing metabolic syndrome were included for the literature review. PubMed was 
subsequently searched using the terms “atypical”, “antipsychotics”, “metabolic”, “syndrome”, 
“comparison”. This yielded 20 results. Only one randomized trial was picked comparing 4 
atypical antipsychotics. Two other studies fit the criteria but only compared two atypicals which 
were already compared in the previous study. PsycInfo was also searched using the terms 
“atypical”, “antipsychotics”, “metabolic”, “syndrome”, and “genes”. 14 results were available. 2 
were selected to highlight the genetic context of developing metabolic syndrome in 





schizophrenic patients and one more study was picked due to its review of two atypical 
antipsychotics’ association with diabetes. PubMed was revisited to find studies that dealt with 
treatment. The search terms used were “metabolic”, “syndrome”, “treatment”, “atypical”, 
“antipsychotics”. One review of 12 studies and another systematic review with a meta-analysis 
were chosen for the literature review. The remaining results from the 3 databases were not 
included due to the low quality nature of the studies or because of topics covered that were not 
relevant to this literature review. 
 Given the widespread use of atypical antipsychotics in the treatment of schizophrenia, 
this literature review will explore the varying degrees of association between the atypical 
antipsychotics used and the development of metabolic syndrome. Furthermore, therapeutic 
options will be explored and recommendations synthesized from the available literature. The 
highlights of this review will be presented via a power point format (See Appendix) to fellow 
graduate students of the Psychiatric and Mental Health Nurse Practitioners program as well as 
the instructors at the University of North Dakota. This literature review as well as the 
presentation will also be shared with colleagues. 
Results 
 The project set out to identify available literature on the topic. The 3-database search 
yielded literature including 7 systematic reviews, 1 systematic reviews with meta-analysis, 1 
randomized-controlled trial, 1 equipoise-stratified randomized trial, 2 cross-sectional studies and 
3 qualitative reviews. The literature picked specifically dealt with metabolic syndrome in the 
setting of atypical antipsychotic use in schizophrenic patients. No guidelines were identified for 
monitoring of metabolic syndrome in this patient population. These patients were more or less 
treated with the guidelines developed for the general population at risk for metabolic syndrome 





(ex. Lipid and glucose monitoring). In addition, there were no specific guidelines regarding 
treatment of metabolic syndrome in schizophrenics who use atypical antipsychotics. As noted in 
this literature review, this unique patient population requires additional care in monitoring as 
well as treatment in addition to the standard of care afforded to the general population with 
metabolic syndrome. 
Discussion 
 This project was successful in identifying the pertinent available literature on the topic of 
metabolic syndrome in patients with schizophrenia who are on atypical antipsychotics. As 
alluded to in the beginning, metabolic syndrome is a major contributor of cardiovascular 
morbidity and mortality in this patient group as well as in the general population. As such, a 
multifaceted approach is necessary to address the problem and reduce the disease burden in this 
very vulnerable patient population. The APRN should integrate the Health Promotions Model 
into caring for these patients by taking into account the various biopsychosocial factors that 
influence the patients’ motives. Adequate symptom control in Schizophrenia empowers patients 
and provides them with the mental stability they need to actively participate in their own care. 
This leads to a better health outcome. The APRN’s provision of care includes prevention, 
screening, timely diagnosis/treatment of metabolic syndrome, making medication adjustments, 
providing counseling and ensuring appropriate close follow-up. Patients with schizophrenia on 
atypical antipsychotics also require every guideline-based disease management offered to the 
general population in order to prevent metabolic syndrome and its dreaded complications. In 
addition, they also require a highly individualized comprehensive care plan that takes into 
account their mental health burden. In addition to implementing the Health Promotions Model, 
the APRN should be knowledgeable about the commonly available atypical antipsychotics along 





with their level of efficacy, side-effect profile including metabolic syndrome, and management 
of their complications. Long-term periodic monitoring of metabolic syndrome parameters 
(glucose, lipid panel, and BMI) is highly recommended. This type of monitoring should also be 
done in schizophrenic patients in general due to biopsychosocial factors that may lead to 
metabolic syndrome independent of treatment with atypical antipsychotics. It is also very 
important to ensure timely follow up for continuity of care. Based on the literature review, the 
spectrum of risk of developing metabolic syndrome with the various atypical antipsychotics is as 
follows from high risk to low risk. clozapine > olanzapine > quetiapine/sertindole > risperidone 
> amisulpride/aripiprazole > ziprasidone. Assessing comparative efficacy between the different 
medications was beyond the scope of this project. The APRN can use this spectrum of risk 
profile to inform point-of-care medical decision-making while treating a schizophrenic patient 
who needs to be on long-term atypical antipsychotic. High side-effect profiles of these 
medications contribute to non-adherence, worsening of schizophrenia-related symptoms and 
inability to follow through with other treatment recommendations. For example, a common 
theme with the literature review was the high attrition rate of the study subjects in most of the 
randomized controlled trials which prevented firm conclusions from being drawn. However, 
comparisons could still be made regarding the side effect profiles of most of these medications. 
Independent of being on atypical antipsychotics, patients with schizophrenia are also at an 
increased risk of developing metabolic syndrome. This is likely due to their poor mental health 
interfering with their ability to make good lifestyle choices. The addition of atypical 
antipsychotics adds to the disease burden. Treating these patients’ metabolic syndrome requires a 
multifaceted approach. The literature review has identified that low dose metformin at 750 mg 
per day combined with lifestyle modifications (ex. health diet, exercise) has shown significant 





benefits through reduction of weight and treatment of hyperglycemia in metabolic syndrome. 
The role of metformin suggested here is primarily for weight loss where as in the general 
population it is used to treat pre-diabetes and diabetes, both of which are components of the 
metabolic syndrome. 
 APRNs, RNs, and LPNs are uniquely situated to improve the outcomes for this patient 
population. Founded on the solid knowledge of the various atypical antipsychotics with their 
efficacy and side-effect profiles, APRNs can better treat schizophrenia improving the quality of 
life and longevity of their patients. RN and LPN health coaches can then perform periodic 
metabolic monitoring, provide encouragement to patients as well as carry out home visits to 
maximize adherence to treatment regimen. Through involvement in research, APRNs can 
implement better research designs that minimize attrition and ensure adequate sample size in 
comparative trials. They can also participate in educating their multidisciplinary colleagues as 
well as the patients about this issue, participate in advocacy and help bring about healthcare 
policy reform. 
Summary 
 In conclusion, metabolic syndrome in schizophrenic patients is a common diagnosis 
associated with cardiovascular morbidity and mortality in line with the general populations. 
Treatment with atypical antipsychotics compounds this risk. Despite the level of attrition of 
study subjects, various randomized controlled trials have established a comparative risk of 
metabolic syndrome among the various atypical antipsychotics. Clozapine and olanzapine have 
been associated with the most risk of metabolic syndrome while ziprasidone and aripiprazole are 
associated with the least amount of risk. Analysis of comparative efficacy was beyond the scope 
of this independent project. Management of metabolic syndrome in this patient population 





includes prevention, screening, neuroleptic medication adjustment, and treatment of medication 
complications including metabolic syndrome. These patients require a multifaceted approach to 
treatment including choosing the right medication, implementing lifestyle modifications and also 
take into account the various biopsychosocial factors that affect their motivation to work toward 
a better outcome. Low dose metformin in conjunction with healthy diet and exercise has shown 
the most benefit in reducing BMI, waist circumference and ultimately metabolic syndrome. The 
APRN should play a leading role in advancing research in this field, helping educate colleagues, 
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